Evidence map›Paper›PMID 34407765›Full record

ArticleBMC immunology2021

Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations.

Louis Szeponik, Filip Ahlmanner, Patrik Sundström, William Rodin, Bengt Gustavsson, Elinor Bexe Lindskog, Yvonne Wettergren, Marianne Quiding-Järbrink

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Immune checkpoints are predominantly co-expressed by clonally expanded CD4Journal of experimental & clinical cancer research : CR · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Louis Szeponik *Department of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Box 435, 405 30, Göteborg, Sweden.
Filip Ahlmanner *Department of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Box 435, 405 30, Göteborg, Sweden.
Patrik SundströmDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Box 435, 405 30, Göteborg, Sweden.
William RodinDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Box 435, 405 30, Göteborg, Sweden.
Bengt GustavssonDepartment of Surgery, Institute of Clinical Sciences, The Sahlgrenska Academy at the University of Gothenburg, Blå stråket 5, 413 45, Göteborg, Sweden.
Elinor Bexe LindskogDepartment of Surgery, Institute of Clinical Sciences, The Sahlgrenska Academy at the University of Gothenburg, Blå stråket 5, 413 45, Göteborg, Sweden.
Yvonne WettergrenDepartment of Surgery, Institute of Clinical Sciences, The Sahlgrenska Academy at the University of Gothenburg, Blå stråket 5, 413 45, Göteborg, Sweden.
Marianne Quiding-JärbrinkDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Box 435, 405 30, Göteborg, Sweden. marianne.quiding@microbio.gu.se.
University of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntratumoral regulatory T cells (Treg) in colon cancer are a heterogeneous cell population, with potential impact on patient outcome. Generally, a high Treg infiltration has been correlated to a worse patient outcome, but it is still unclear how the composition of different Treg subsets affects patient relapse and survival. In this study, we used mass and flow cytometry to characterize Treg in colon tumors and corresponding unaffected tissue, followed by a correlation to clinical parameters and patient outcome.

resultsUsing mass cytometry, we defined 13 clusters of intestinal Treg, three of which were enriched in the tumors. The two most enriched clusters were defined by their expression of the proliferation marker Ki67 and CD56, respectively. The Treg accumulating in the tumors expressed inducible T-cell co-stimulator (ICOS), OX-40, and CD39, indicating that they were effector Treg (eTreg). Intratumoral CD39

conclusionsThis study uncovers novel subsets of tumor-infiltrating Treg in colon cancer, and suggests that CD39 may be a potential therapeutic target in patients with microsatellite stable colon tumors, which are usually refractory to checkpoint blockade therapy.

Indexed as

AdultAgedAged, 80 and overAntigens, CDApyraseColonic NeoplasmsFemaleForkhead Transcription FactorsHumansLymphocyte ActivationLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm StagingPrognosisSurvival AnalysisAntigens, CDApyraseCD39 antigenForkhead Transcription FactorsFOXP3 protein, humanCancer-specific survivalCD39Colon cancerRegulatory T cell

Identifiers

PMID34407765
PMCPMC8375143
OpenAlexW3194517715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.